NEW YORK, Jan 2, 2026, 11:40 ET — Regular session
- Intelligent Bio Solutions shares were down 12.1% at $8.38 in late morning trading.
- The slide follows a $10 million at-the-market private placement that includes two tranches of warrants.
- INBS also flagged a new manufacturing partnership it expects to lift margins ahead of a planned U.S. entry in 2026.
Shares of Intelligent Bio Solutions Inc slid on Friday as investors digested the micro-cap medtech company’s $10 million private placement announced late Wednesday. The stock was down 12.1% at $8.38 by 11:25 a.m. ET.
The pullback comes after the stock more than doubled on Dec. 31 following news of a manufacturing partnership aimed at scaling production of its fingerprint-based drug screening reader.
The timing matters because INBS is trying to ramp production and shore up supply as it targets a 2026 U.S. market entry, while also tapping capital markets that can quickly reshape the share count. Traders often treat discounted financings with warrants as an overhang because they can add to the number of shares available for sale.
INBS said it agreed to sell 2,298,850 common shares — or prefunded warrants in their place — alongside two series of warrants that each cover up to another 2,298,850 shares, for expected gross proceeds of about $10 million before fees. The combined purchase price was $4.35 per share and associated warrants, and the transaction was priced at the market under Nasdaq rules, the company said.
A private placement is a sale of securities directly to investors rather than through a public offering. Warrants are options that allow holders to buy shares later at a set price.
The Series K-1 and K-2 warrants carry an exercise price of $4.10 a share and are exercisable immediately upon issuance, INBS said. It expects to close the financing on or about Jan. 2 and intends to use proceeds for working capital and general corporate purposes.
The company also said it would file a resale registration statement within 10 calendar days and use its best efforts to have it declared effective within 45 days. Ladenburg Thalmann & Co. is acting as placement agent, it said.
Separately, INBS said it struck a manufacturing partnership with Syrma Johari MedTech to expand production of its Intelligent Fingerprinting Drug Screening Reader, expecting annual production cost savings of more than 40% and an improvement of roughly 20 percentage points in gross margin — the profit after production costs. “Partnering with Syrma Johari is a strategically significant milestone for our business,” said Callistus Sequeira, the company’s vice president of global quality and operations. BioSpace
INBS markets a non-invasive drug screening system that analyzes fingerprint sweat and delivers results in under 10 minutes, according to the company. It says it currently sells primarily outside the United States into industries such as construction, transport and logistics, and mining.
Friday’s decline underscored investor sensitivity to dilution in thinly traded names. The private placement includes warrants for up to about 4.6 million additional shares if exercised in full, on top of the shares being sold.
INBS opened at $7.80 and traded between $7.43 and $8.90 so far on Friday, with about 1.40 million shares changing hands by 11:25 a.m. ET. The company’s market value was about $8 million, according to Benzinga data.
Investors are likely to focus next on whether the financing closes as expected and on follow-up SEC filings that spell out final terms. The manufacturing ramp and any update to the company’s 2026 U.S. launch plans remain the next catalysts for fundamentals-driven trading.
